These are top 10 stocks traded on the Robinhood UK platform in July
Astria Therapeutics (NASDAQ:ATXS) stock rose Monday following H.C. Wainwright’s reiteration of a buy rating and $16.00 price target on the company’s shares. According to InvestingPro data, analysts’ targets range from $16 to $47, with a strong buy consensus, suggesting significant upside potential from the current $5.72 price level.
The firm’s decision came after Astria announced positive initial safety and efficacy results from its ALPHA-SOLAR long-term open label study of navenibart in hereditary angioedema (HAE) patients at the European Academy of Allergy and Clinical Immunology ’25 conference. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt on its balance sheet, though it’s currently burning through cash as it advances its clinical programs.
All 16 target enrollment participants from the previous ALPHA-STAR trial elected to enroll in the ALPHA-SOLAR study, with patients from Cohorts 1 and 2 entering Arm A, while Cohort 3 patients joined Arm B of the new study.
The initial long-term results, with patients now 12-18 months on navenibart, demonstrated a robust overall reduction in monthly attack rates and supported the potential for administering the treatment every 3 and every 6 months.
H.C. Wainwright noted these data continue to support Astria’s ongoing global pivotal Phase 3 ALPHA-ORBIT trial, which is evaluating both dosing regimens, and stated that navenibart’s profile "bolster[s] our confidence and demonstrate[s] its potential to be the market-leading HAE therapy."
In other recent news, Astria Therapeutics reported positive initial results from its ALPHA-SOLAR long-term trial of navenibart, a treatment for hereditary angioedema (HAE). The trial demonstrated a significant reduction in monthly attack rates, with some patients experiencing a 95% reduction. The drug was well-tolerated, with no severe treatment-related adverse events reported. Additionally, Citizens JMP analyst Jonathan Wolleben reaffirmed a Market Outperform rating and maintained a $25 price target for Astria Therapeutics, expressing optimism about navenibart’s potential compared to existing treatments. Cantor Fitzgerald also maintained an Overweight rating with a $47 price target, highlighting the company’s financial stability and the upcoming release of Phase 3 study data. Furthermore, JMP Securities adjusted its price target to $25 from $26, while still rating the stock as Market Outperform, emphasizing the importance of upcoming data releases. The company is continuing its efforts with navenibart, which is in Phase 3 development, and another candidate, STAR-0310, for atopic dermatitis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.